skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Role of atazanavir in the treatment of HIV infection

Review

(2971) Views  (567) Full article downloads

Authors: Pablo Rivas, Judit Morello, Carolina Garrido, Sonia Rodríguez-Nóvoa, Vincent Soriano

Published Date December 2008 Volume 2009:5 Pages 99 - 116
DOI: http://dx.doi.org/10.2147/TCRM.S3114

Pablo Rivas1, Judit Morello2, Carolina Garrido1, Sonia Rodríguez-Nóvoa2, Vincent Soriano1

1Department of Infectious Diseases; 2Pharmacology Unit, Hospital Carlos III, Madrid, Spain

Abstract: Atazanavir (ATV) is one of the latest protease inhibitors (PI) approved for the treatment of HIV infection. The drug has a relatively long-life (∼7 h) and large inhibitory quotient which allows once daily administration. It is generally well tolerated and the main side effect is hyperbilirubinemia, since ATV inhibits the hepatic uridin-glucoronyl-transferase. A signature mutation at the protease gene, I50L, may confer loss of susceptibility to the drug. Interestingly, it produces hypersusceptibility to all other PIs. When ATV is pharmacokinetically boosted with ritonavir (r) 100 mg/day, a greater genetic barrier for resistance is achieved, and generally more than 3 major PI resistance associated mutations are needed to result in ATV resistance. In drug-naïve subjects, regimens based on ATV/r have shown non-inferiority compared to lopinavir (LPV)/r (CASTLE study) or fosamprenavir/r (ALERT trial), generally with improved tolerance (less diarrhea and dyslipidemia). Given its good tolerance and convenience, ATV has been proven to be successful as a simplification strategy in switch studies (ie, SWAN and SLOAT) conducted in patients with complete virological suppression under other PI-based regimens. Finally, ATV/r-based combinations have shown to be equivalent in terms of viral response to other PI/r-containing regimens, including LPV/r, in rescue interventions in patients failing other PI regimens (ie, studies AI424-045 and NADIS).

Keywords: atazanavir, HIV, protease inhibitors, drug resistance






 

Other articles by Dr Vincent Soriano



Readers of this article also read:

Life-threatening hemorrhage following subcutaneous heparin therapy
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Long-term treatment of patients with HIV-1: the role of atazanavir
Clinical utility and long-term use of atazanavir in the treatment of HIV-1 infection
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum